This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

CompLaw: Nordic
17 & 18 March 2026
Hilton SlussenStockholm, Sweden

Morten Nissen
Partner at Bird & Bird
Speaker

Profile

International antitrust lawyer admitted to the Danish bar in 1995 and the Brussels bar in 2000. Morten is a member of the Steering Committee of the EU & Competition group in Bird & Bird LLP.

Morten works out of Copenhagen, Denmark, but has deep-seated European experience and network anchored in 12 years of working in Brussels. Whilst in Brussels Morten was ranked as a leading competition law specialist at European level by legal directories such as Legal 500 ("...provides ‘excellent guidance on key issues'") and Chambers & Partners (“wins praise for his "down-to-earth and frank style."). He was awarded a “Commendation” in the Financial Times’ “2011 Innovative Lawyer Report” as one of 23 lawyers worldwide. Morten was recently awarded the Client Choice Awards 2019 by Lexology in the Competition & Antitrust category for Denmark.

Morten's focus is primarily on restrictive practices, abuse of dominance and State aid, on the side of multinationals and industry associations. He particularly focuses on using competition law as a tool to obtain specific and measurable commercial goals. Morten has solid litigation experience before the European courts in Luxembourg, which includes winning four appeal cases against the European Commission. Morten has particular experience in the following industry sectors: passenger transport, IT & software, pharmaceuticals & medical devices, media & music rights, telecoms, issues common to international industry associations and international payment systems.

He is on the Advisory Board of “World Competition, Law and Economics Journal” (Kluwer) and a co-author of “Guide to EU Pharmaceutical Regulatory Law” (Kluwer).

Agenda Sessions

  • Article 102: Update on the Draft Guidelines & Significant Recent Cases

    13:30